The Role of Hypoxia in the Differentiation of P19 Embryonal Carcinoma Cells into Dopaminergic Neurons

Nervous system development at early stage is in hypoxic environment. Very little is known about the role of hypoxia in neuronal development. P19 embryonal carcinoma (EC) cells are a widely used model for studying early neuronal development. In this study we investigated the roles of hypoxia in differentiation of dopaminergic neurons derived from P19 EC cells. Results demonstrate that hypoxia increases the percentage of differentiated neurons, especially neurons of dopaminergic phenotype. To investigate the potential mechanism involved in hypoxia promoted differentiation of dopaminergic neurons, we measured the expression of hypoxia-inducible factor 1α (HIF-1α), based on its characteristic response to hypoxia. The result shows that HIF-1α mRNA level in P19 EC cells increases after hypoxia treatment. It is known that HIF-1α regulates the expression of tyrosine hydroxylase (TH) gene through binding to its promoter. Therefore, we propose that the underlying mechanism for hypoxia promoted differentiation of dopaminergic neurons was mediated by HIF-1α up-regulation under hypoxia. Yue Wang—Co-first author. Special Issue in honor of Dr. Ji-Sheng Han.     

E2F1 介导8-氯-腺苷引起的人肺癌细胞H1299的凋亡

8-氯-腺苷（8-Cl-adenosine,8-Cl-Ado）可诱导人非小细胞性肺癌细胞H1299发生凋亡,但其分子机制还没有阐明．首先用四唑盐（MTT）比色法检测了8-Cl-Ado 对H1299 细胞的生长抑制作用．进一步采用蛋白质免疫印迹法(Western blotting) 检测了8-Cl-Ado 处理H1299细胞后,procaspase-3 的激活情况以及E2F1的蛋白水平．通过用pcDNA-HA-E2F1表达载体和pSUPER-E2F1 RNA 干扰载体分别转染H1299 细胞,研究在E2F1 过表达和RNA 干扰（RNA interference, RNAi）两种情况下对凋亡的影响．实验结果表明,8-Cl-Ado可抑制H1299 细胞的生长,激活凋亡关键执行蛋白procaspase-3,升高E2F1 蛋白水平．当E2F1 过表达后,同时伴有procaspase-3 的激活,而E2F1 表达受到抑制后,与对照相比,8-Cl-Ado 引起的procaspase-3 的激活被明显抑制,说明E2F1 介导8-Cl-Ado 引起的人肺癌细胞H1299 的凋亡．     

靶向E2F1的shRNA抑制眼内视网膜母细胞瘤生长

视网膜母细胞瘤(retinoblastoma,RB)中由于Rb基因缺失或失活,转录调控因子E2F1始终处于活化状态,细胞不断增殖,E2F1活性增加是恶性肿瘤的普遍现象．根据人E2F1基因设计了3段shRNA,构建RNA干扰表达载体pSilencer-shE2F1,瞬时转染人视网膜母细胞瘤细胞株HXO-Rb-44和人肝癌细胞株SMMC-7721,通过荧光定量PCR检测E2F1表达水平的变化,PI (碘化丙锭)染色检测细胞周期各时相细胞数量以检测其对细胞周期的影响．根据筛选出的有效shRNA序列构建腺病毒载体并包装出腺病毒Ad-shE2F1,在裸鼠前房模型中,体外按50 moi的感染系数感染稳定表达绿色荧光蛋白(GFP)的人视网膜母细胞瘤细胞株48 h后,收集细胞,将2×10⁵细胞注射到裸鼠眼前房内,连续观察眼内肿瘤细胞生长情况并拍照记录．通过转染肿瘤细胞株检测E2F1转录水平,筛选到1个能明显抑制肿瘤细胞内E2F1表达的shRNA序列,并使细胞周期中S期细胞数减少．经Ad-shE2F1感染的RB肿瘤细胞与对照相比较,其在裸鼠眼前房内肿瘤生长减缓．结果说明,有效抑制hE2F1表达的shRNA具有抑制体内外人视网膜母细胞瘤生长的作用．     

非典型E2F转录因子对细胞周期的调控及其功能

E2F家族转录因子是细胞周期调控网络中的重要环节之一,对细胞的增殖、分化和凋亡进行调节,并参与多种生理和病理过程。近年来,关于哺乳动物中E2F转录因子的生物学作用研究取得了很大进展,并鉴定出两个非典型的E2F家族成员：E2F7和E2F8。与典型的E2F转录因子相比,非典型E2F蛋白结构中含有两个相同的DNA结合域,对靶基因转录的调控不依赖于二聚化蛋白。非典型E2F蛋白进入细胞核后,通过与经典的E2F靶基因启动子结合,发挥转录抑制作用并调节细胞周期的进程,从而对细胞的大小、多倍化、增殖、分化和凋亡进行调控。随着基因敲除模型的建立和完善,使得进一步研究非典型E2F转录因子在不同组织或器官中的生物学作用成为可能。非典型E2F在胚胎发育、血管发生及造血系统中均发挥重要作用。另外,肿瘤细胞中典型E2F和非典型E2F的表达比例发生改变,说明非典型E2F成员还参与肿瘤的发生发展。该文综述了近年来关于非典型E2F转录因子的表达、调节及其生理病理作用的研究进展。     

转录因子E2F1抑制CREG表达调控体外培养的人血管平滑肌细胞分化

为探讨转录因子E2F1在血管平滑肌细胞(vascular smooth muscle cells,VSMCs)表型转化中的作用及其对E1A激活基因阻遏子(cellular repressor of E1A-stimulated genes,CREG)表达调控的分子机制,应用生物信息学方法,定位人CREG(hCREG)基因启动子并确定转录因子E2F1在hCREG启动子区的结合位点,PCR方法克隆并构建hCREG基因启动子绿色荧光报告基因载体,以hCREG启动子区E2F1结合位点为模板,化学合成E2F1寡聚脱氧核苷酸(ODN)和错配E2F1ODN,利用转录因子"诱骗(Decoy)"策略,用E2F1ODN转染体外培养的VSMCs以阻断E2F1与hCREG基因启动子区的结合,蛋白质印迹(Western blot)分析检测阻断前后细胞内hCREG蛋白、报告基因绿色荧光蛋白(green fluorescent protein,GFP)和平滑肌细胞分化标志蛋白SMα-actin表达变化.结果显示:分化表型HITASY细胞中E2F1表达下调伴出核转位,而增殖表型的HITASY细胞中E2F1蛋白表达明显增加且定位于核内.进一步应用FuGene6瞬时转染E2F1ODN和错配E2F1ODN于体外培养HITASY细胞中,蛋白质印迹分析发现,转染E2F1ODN后,HITASY细胞中hCREG、SMα-actin和GFP表达均较未阻断组及错配组细胞明显增加.上述研究结果证实,E2F1是hCREG基因转录的重要调控因子,能够直接结合于hCREG启动子区阻遏hCREG表达,参与hCREG蛋白对VSMCs表型转化的调控作用.     

DNA-damage response control of E2F7 and E2F8

Here, we report that the two recently identified E2F subunits, E2F7 and E2F8, are induced in cells treated with DNA-damaging agents where they have an important role in dictating the outcome of the DNA-damage response. The DNA-damage-dependent induction coincides with the binding of E2F7 and E2F8 to the promoters of certain E2F-responsive genes, most notably that of the E2F1 gene, in which E2F7 and E2F8 coexist in a DNA-binding complex. As a consequence, E2F7 and E2F8 repress E2F target genes, such as E2F1, and reducing the level of each subunit results in an increase in E2F1 expression and activity. Importantly, depletion of either E2F7 or E2F8 prevents the cell-cycle effects that occur in response to DNA damage. Thus, E2F7 and E2F8 act upstream of E2F1, and influence the ability of cells to undergo a DNA-damage response. E2F7 and E2F8, therefore, underpin the DNA-damage response.     

E2F1 mediates DNA damage and apoptosis through HCF‐1 and the MLL family of histone methyltransferases

E2F1 is a key positive regulator of human cell proliferation and its activity is altered in essentially all human cancers. Deregulation of E2F1 leads to oncogenic DNA damage and anti‐oncogenic apoptosis. The molecular mechanisms by which E2F1 mediates these two processes are poorly understood but are important for understanding cancer progression. During the G1‐to‐S phase transition, E2F1 associates through a short DHQY sequence with the cell‐cycle regulator HCF‐1 together with the mixed‐lineage leukaemia (MLL) family of histone H3 lysine 4 (H3K4) methyltransferases. We show here that the DHQY HCF‐1‐binding sequence permits E2F1 to stimulate both DNA damage and apoptosis, and that HCF‐1 and the MLL family of H3K4 methyltransferases have important functions in these processes. Thus, HCF‐1 has a broader role in E2F1 function than appreciated earlier. Indeed, sequence changes in the E2F1 HCF‐1‐binding site can modulate both up and down the ability of E2F1 to induce apoptosis indicating that HCF‐1 association with E2F1 is a regulator of E2F1‐induced apoptosis.     

E2F-1- and E2Ftr-mediated apoptosis: the role of DREAM and HRK

E2F-1-deleted mutant, 'truncated E2F' (E2Ftr, E2F-1[1-375]), lacking the carboxy-terminal transactivation domain, was shown to be more potent at inducing cancer cell apoptosis than wild-type E2F-1 (wtE2F-1; full-length E2F-1). Mechanisms by which wtE2F-1 and E2Ftr induce apoptosis, however, are not fully elucidated. Our study demonstrates molecular effects of pro-apoptotic BH3-only Bcl-2 family member Harakiri (Hrk) in wtE2F-1- and E2Ftr-induced melanoma cell apoptosis. We found that Hrk mRNA and Harakiri (HRK) protein expression was highly up-regulated in melanoma cells in response to wtE2F-1 and E2Ftr overexpression. HRK up-regulation did not require the E2F-1 transactivation domain. In addition, Hrk gene up-regulation and HRK protein expression did not require p53 in cancer cells. Hrk knockdown by Hrk siRNA was associated with significantly reduced wtE2F-1- and E2Ftr-induced apoptosis. We also found that an upstream factor, 'downstream regulatory element antagonist modulator' (DREAM), may be involved in HRK-mediated apoptosis in response to wtE2F-1 and E2Ftr overexpression. DREAM expression levels increased following wtE2F-1 and E2Ftr overexpression. Western blotting detected increased DREAM primarily in dimeric form. The homodimerization of DREAM resulting from wtE2F-1 and E2Ftr overexpression may contribute to the decreased binding activity of DREAM to the 3'-untranslated region of the Hrk gene as shown by electromobility shift assay. Results showed wtE2F-1- and E2Ftr-induced apoptosis is partially mediated by HRK. HRK function is regulated in response to DREAM. Our findings contribute to understanding the mechanisms that regulate wtE2F-1- and E2Ftr-induced apoptosis and provide insights into the further evaluation of how E2Ftr-induced apoptosis may be used for therapeutic gain.